RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Meccanismi cellulari e molecolari coinvolti nella regolazione della risposta immune adattiva
• 2 - Il fenomeno della cross-presentazione ed i segnali immunomodulatori nella genesi di patologie infettive ed autoimmuni
• 3 - Nuove strategie immunomodulatorie nella Malattia di Graves: ruolo delle chemochine e delle cellule T regolatorie
• 4 - Nuove prospettive sull'immunità innata e l'immunoterapia.
• 5 - Sintesi di sistemi nanostrutturati a base saccaridica, polivalenti e multifunzionali, per l'attivazione della risposta immunitaria
• 6 - Modulazione della tolleranza nell'immunità, autoimmunità e nei trapianti.
• 7 - Meccanismi cellulari e molecolari coinvolti nella regolazione della risposta immunitaria
• 8 - RUOLO DI AGENTI INFETTIVI E DELL'INFIAMMAZIONE CORRELATA ALLA RISPOSTA IMMUNITARIA ADATTATIVA NELLA PATOGENESI DELLE SINDROMI CORONARICHE ACUTE
• 9 - Il sistema GITR/GITRL nelle malattie a patogenesi autoimmunitaria/infiammatoria: un bersaglio per la terapia farmacologica
• 10 - Le interazioni tra tumore ed ospite: meccanismi di immunosoppressione/tolleranza e di attivazione della risposta immune

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • PATOLOGIA GENERALE
  • MICROBIOLOGIA E MICROBIOLOGIA CLINICA
  • MALATTIE INFETTIVE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Lazio

Bibliografia

1. Richie TL. (2002). Progress and challenges for malaria vaccines.
Nature. 415:694-701.

2. Struik SS. (2004). Does malaria suffer from lack of memory?
Immunol Rev. 201:268-90.

3. Kemp K. (2002). Acute P. falciparum malaria induces a loss of CD28- T IFN-gamma producing cells.Parasite Immunol. 24:545-8.

4. Urban BC. (1999). Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature. 400:73-7.

5. Moorthy VS. (2004). Malaria vaccine developments. Lancet.363:150-6.

6. Alonso PL. (2004). Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 364:1411-20.

7. Ocana-Morgner C. (2003). Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med. 197:143-51.

8. Hisaeda, Y. (2004). Escape of malaria parasites from host immunity requires CD4+CD25+ regulatory T cells, Nature Medicine 10 29–30.

9. Urban BC. (2001). A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci U S A. 98:8750-5.

10. Hill, A.V.S. (1991). Common west African HLA antigens are associated with protection from severe malaria. Nature, 352, 595-600.

11. Sjoberg K. (1992). Genetic regulation of human anti-malarial antibodies in twins. Proc Natl Acad Sci U S A, 892, 2101-2104.

12. Rihet P. (1998). Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am J Hum Gen, 63, 498-505.

13. Aitman, T.J. (2000). Malaria susceptibility and CD36 mutation. Nature, 405, 1015-6.

14. Pain A. (2001). A non-sense mutation in Cd36 gene is associated with protection from severe malaria. Lancet, 357, 1502-3.

15. Cockburn, I.A. (2004). A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A, 101, 272-7.

16. Fernandez-Reyes. (1997). A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet, 6, 1357-60.

17. Kun, J.F.(1999). Association of the ICAM-1Kilifi mutation with protection against severe malaria in Lambarene, Gabon. Am J Trop Med Hyg, 61, 776-9.

18. Aucan, C. (2003). Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in The Gambia. Genes Immun, 4, 275-82.

19. Koch, O. (2002). IFNGR1 Gene Promoter Polymorphisms and Susceptibility to Cerebral Malaria. J Infect Dis, 185, 1684-7.

20. Morahan G. (2002). A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun.3:414-8.

21. Luoni G. (2001). Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa. Genes Immun. 2: 411-414.

22. Luty, A.J. (1998). Mannose-binding lectin plasma levels and gene polymorphisms in Plasmodium falciparum malaria. J Infect Dis, 178, 1221-4.

23. Burgner, D. (1998). Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet, 352, 1193-4.

24. Hobbs, M.R. (2002). A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection
from severe malaria in Tanzanian and Kenyan children. Lancet, 360, 1468-75.

25. McGuire, W. (1994). Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature, 371, 508-510.

26. Knight, J.C. (1999). A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet, 22, 145-50.

27. Sabeti, P.C. (2002). Detecting recent positive selection in the human genome from haplotype structure. Nature, 419, 832-837.

28. Sabeti, P.C. (2002). CD40L association with protection from severe malaria. Genes Immun, 3, 286-91.

29. Modiano, D. (1996). Different response to Plasmodium falciparum malaria in West African sympatric ethnic groups. Proc Natl Acad Sci U S A, 93, 13206-13211.

30. Dolo A. (2005). Difference in susceptibility to malaria between two simpatryc ethnic groups in Mali. Am J Trop Med Hyg 72(3):243-248.

31. Allsopp C.E.M. (1992). Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am J Hum Gen, 50, 411-21.

32. Modiano D. (2001). HLA class I in three West African ethnic groups: genetic distances from sub-Saharan and Caucasoid populations. Tissue Antigens.;57:128-37.

33. Modiano D. (2001). The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. Trans R Soc Trop Med Hyg.;95:149-52.

34. Verra F. (2004). IL4-589C/T polymorphism and IgE levels in severe malaria. Acta Trop.;90:205-9.

35. Modiano D. (1998) . Humoral response to Plasmodium falciparum Pf155/ring-infected erythrocyte surface antigen and Pf332 in three sympatric ethnic groups of Burkina Faso. Am J Trop Med Hyg.;58:220-4.

36. Sakaguchi S. (2003). Regulatory T cells: mediating compromises between host and parasite. Nat Immunol. 4:10-1.

37. Sakaguchi S. (2001). Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev.182:18-32.

38. Shevach EM. (2002). CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2:389-400.

39. Belkaid Y. (2002). CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. ;420:502-7.

40. Aseffa A. (2002). The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J Immunol. 169:3232-41.

41. Xu D. (2003). CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 170:394-9.

42. Iwashiro M. (2001). Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci U S A.;98:9226-30.

43. Montagnoli C. (2002). B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol.169:6298-308.

44. Hori S. (2002). CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol. 32:1282-91.

45. Singh B. (2001). Control of intestinal inflammation by regulatory T cells. Immunol Rev. 182:190-200.

46. Bryceson AD. (1976). Splenomegaly in Northern Nigeria. Acta Trop. 33:185-214.

47. Nakase H. (2003). Effect of CpG methylation on RAG1/RAG2 reactivity: implications of direct and indirect mechanisms for controlling V(D)J cleavage. EMBO Rep. 4:774-80.

48. Smits HH. (2005). Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 26:123-129.

49. Palucka K. (2002). How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol. 14:420-431.

50. Masuyama J. (2002). A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells. J Immunol. 169:3710-3716.

51. Lin CH. (2003). Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol. 33:626-638.

52. Kapsenberg ML. (2003). Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 3:984-993.

53. Pasare C. (2003). Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 299:1033-1036.

54. Netea MG. (2004). Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol. 172: 3712-3718.

Parole Chiave

MALARIA, RESISTENZA, SUSCETTIBILITA', GENETICA, RISPOSTA IMMUNITARIA, GRUPPI ETNICI, CELLULE T REGOLATORIE, CELLULE DENDRITICHE